Literature DB >> 16182377

Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis.

Shigeaki Suzuki1, Takashi Satoh, Hidekata Yasuoka, Yasuhito Hamaguchi, Kortaro Tanaka, Yutaka Kawakami, Norihiro Suzuki, Masataka Kuwana.   

Abstract

Sera from patients with myasthenia gravis (MG) were screened for autoantibodies to skeletal muscle-specific antigens by immunoprecipitation assay, using rhabdomyosarcoma and leukemia cell lines. Eleven of 61 MG sera immunoprecipitated a rhabdomyosarcoma-specific 70-kDa protein, which was identified as the voltage-gated K+ channel 1.4 (Kv1.4). This antibody specificity was not detected in 30 patients with polymyositis/dermatomyositis, 9 with thymoma alone, or 30 healthy controls. Clinical features associated with anti-Kv1.4 antibody included bulbar involvement, myasthenic crisis, thymoma, myocarditis, and QT prolongation on electrocardiogram. These findings suggest that anti-Kv1.4 antibody is a novel autoantibody associated with a severe MG subset and thymoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182377     DOI: 10.1016/j.jneuroim.2005.08.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  24 in total

1.  Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis.

Authors:  Fredrik Romi; Shigeaki Suzuki; Norihiro Suzuki; Axel Petzold; Gordon T Plant; Nils Erik Gilhus
Journal:  J Neurol       Date:  2011-12-14       Impact factor: 4.849

Review 2.  Neuro-ophthalmology update.

Authors:  Konrad P Weber; Dominik Straumann
Journal:  J Neurol       Date:  2013-09-26       Impact factor: 4.849

Review 3.  The domain and conformational organization in potassium voltage-gated ion channels.

Authors:  Anastasia V Pischalnikova; Olga S Sokolova
Journal:  J Neuroimmune Pharmacol       Date:  2008-10-03       Impact factor: 4.147

4.  A case of myasthenia gravis with cardiac fibrosis and easily provoked sustained ventricular tachycardia.

Authors:  Aiko Sakamoto; Miyuki Yamamoto; Masao Takahashi; Kohsuke Ajiki; Satoshi Ota; Akimichi Murakami; Makoto Mutou; Kamon Imai; Takahiro Maruta; Hiroaki Yoshikawa; Nobukazu Ishizaka; Hiroshi Yamashita; Yasunobu Hirata; Ryozo Nagai
Journal:  J Cardiol Cases       Date:  2010-02-19

5.  Both binding and blocking antibodies correlate with disease severity in myasthenia gravis.

Authors:  Sa-Yoon Kang; Jung-Hwan Oh; Sook Keun Song; Jung Seok Lee; Jay Chol Choi; Ji-Hoon Kang
Journal:  Neurol Sci       Date:  2015-05-12       Impact factor: 3.307

6.  Skeletal Muscle Involvement in Antisynthetase Syndrome.

Authors:  Eri Noguchi; Akinori Uruha; Shigeaki Suzuki; Kohei Hamanaka; Yuko Ohnuki; Jun Tsugawa; Yurika Watanabe; Jin Nakahara; Takashi Shiina; Norihiro Suzuki; Ichizo Nishino
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

7.  Multiscale modelling of relationships between protein classes and drug behavior across all diseases using the CANDO platform.

Authors:  Geetika Sethi; Gaurav Chopra; Ram Samudrala
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

Review 8.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

Review 9.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 10.  Electroimmunology and cardiac arrhythmia.

Authors:  Jana Grune; Masahiro Yamazoe; Matthias Nahrendorf
Journal:  Nat Rev Cardiol       Date:  2021-03-02       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.